At what price were the GSK (GLAXF) Share Reward Plan shares acquired?

All reported acquisitions were made at a price of £21.7087 per Ordinary Share. This single price applied to both partnership shares purchased and matching shares awarded under GSK’s Share Reward Plan, with trading taking place on the London Stock Exchange (XLON).

GSK (GLAXF) leaders receive Ordinary Shares via Share Reward Plan

Q: Which GSK (GLAXF) executives acquired shares under the Share Reward Plan?

Executives acquiring shares included the President, Europe; Chief Financial Officer; SVP and Group General Counsel; President, Corporate Development; President, Global Supply Chain; President, Global Affairs; CEO of ViiV Healthcare and President, Global Health; and the SVP & Company Secretary, along with a person closely associated with the President, Europe.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reported that several senior executives and one person closely associated acquired small numbers of Ordinary Shares under the Company’s Share Reward Plan. On 13 April 2026, each transaction involved GSK Ordinary Shares of 31¼ pence, traded on the London Stock Exchange.

Participants included the President, Europe; Chief Financial Officer; SVP and Group General Counsel; President, Corporate Development; President, Global Supply Chain; President, Global Affairs; CEO of ViiV Healthcare and President, Global Health; the SVP & Company Secretary; and a person closely associated with the President, Europe. Individual acquisitions ranged from 10 to 12 shares at £21.7087 per share, split between partnership and matching shares under the plan.

Key Figures

Share price: £21.7087 per share Lynn Baxter shares: 12 shares Julie Brown shares: 10 shares +2 more

5 metrics

Share price £21.7087 per share Price for all Share Reward Plan acquisitions on 13 April 2026

Lynn Baxter shares 12 shares 6 partnership and 6 matching shares under Share Reward Plan

Julie Brown shares 10 shares 5 partnership and 5 matching shares under Share Reward Plan

James Ford shares 10 shares 5 partnership and 5 matching shares under Share Reward Plan

Neil Falkingham shares 12 shares PCA of President, Europe; 6 partnership and 6 matching shares

Key Terms

PDMR, person closely associated, Share Reward Plan, Ordinary Shares, +1 more

5 terms

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

person closely associated regulatory

"Details of PDMR/person closely associated with them ('PCA')"

Ordinary Shares financial

"Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

LEI regulatory

"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

Form 6-K: How Foreign Companies Report to the SEC →

04/14/2026 - 11:22 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	6 (partnership shares)
			£21.7087	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	5 (partnership shares)
			£21.7087	5 (matching shares)

d)	Aggregated information
	Aggregated volume Price	10 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	5 (partnership shares)
			£21.7087	5 (matching shares)

d)	Aggregated information
	Aggregated volume Price	10 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	5 (partnership shares)
			£21.7087	5 (matching shares)

d)	Aggregated information
	Aggregated volume Price	10 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	6 (partnership shares)
			£21.7087	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	6 (partnership shares)
			£21.7087	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	6 (partnership shares)
			£21.7087	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	6 (partnership shares)
			£21.7087	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.7087	6 (partnership shares)
			£21.7087	6 (matching shares)

d)	Aggregated information
	Aggregated volume Price	12 Ordinary Shares £21.7087
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: April 14, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR

FAQ

What did GSK plc (GLAXF) disclose in this Form 6-K?

GSK plc disclosed that several senior executives and one person closely associated acquired small amounts of Ordinary Shares under the Company’s Share Reward Plan. These routine share acquisitions occurred on 13 April 2026 on the London Stock Exchange at a price of £21.7087 per share.

How many GSK (GLAXF) shares did each participating executive acquire?

Each participating executive acquired between 10 and 12 GSK Ordinary Shares. For example, Lynn Baxter and Regis Simard each acquired 12 shares, while Julie Brown, James Ford and David Redfern each acquired 10 shares. These totals combine partnership and matching shares granted under the Share Reward Plan.

What type of GSK (GLAXF) security was involved in these transactions?

The transactions involved GSK Ordinary Shares of 31¼ pence each, identified by ISIN GB00BN7SWP63. These are the company’s standard equity securities, and in this case they were acquired as part of the Company’s Share Reward Plan on the London Stock Exchange.